Clinical and histologic features of azithromycin-induced liver injury

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 2, 2015, Pages 369-376.e3

  Martinez, Melissa A ^a   Vuppalanchi, Raj ^a   Fontana, Robert J ^b   Stolz, Andrew ^c   Kleiner, David E ^d   Hayashi, Paul H ^f   Gu, Jiezhun ^g   Hoofnagle, Jay H ^e   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antibiotic; DILI; Liver toxicity; Macrolide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AZITHROMYCIN; BILIRUBIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; AZITHROMYCIN INDUCED LIVER INJURY; BRONCHITIS; CHILD; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; HYPERSENSITIVITY; JAUNDICE; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NAUSEA; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY; PRURITUS; SCHOOL CHILD; SKIN MANIFESTATION; TOXIC HEPATITIS; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; CYTOCHEMISTRY; INFANT; LIVER; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL; TIME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; DRUG-INDUCED LIVER INJURY; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; INFANT; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 84927691893     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.07.054     Document Type: Article

References (33)

1. Lee W.M. Acute liver failure in the United States. Semin Liver Dis 2003, 23:217-226.
2. Reuben A., Koch D.G., Lee W.M., et al. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
3. Temple R.J., Himmel M.H. Safety of newly approved drugs: implications for prescribing. JAMA 2002, 287:2273-2275.
4. Lasser K.E., Allen P.D., Woolhandler S.J., et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002, 287:2215-2220.
5. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934. 1934 e1-4.
6. Robles M., Toscano E., Cotta J., et al. Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. Curr Drug Saf 2010, 5:212-222.
7. George D.K., Crawford D.H. Antibacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf 1996, 15:79-85.
8. Andrade R.J., Tulkens P.M. Hepatic safety of antibiotics used in primary care. JAntimicrob Chemother 2011, 66:1431-1446.
9. Viluksela M., Hanhijarvi H., Husband R.F., et al. Comparative liver toxicity of various erythromycin derivatives in animals. JAntimicrob Chemother 1988, 21(Suppl D):9-27.
10. Braun P. Hepatotoxicity of erythromycin. JInfect Dis 1969, 119:300-306.
11. Lloyd-Still J.D., Sherman J.O., Boggs J., et al. Erythromycin estolate hepatotoxicity. Am J Dis Child 1978, 132:320.
12. Hicks L.A., Taylor T.H., Hunkler R.J. U.S. outpatient antibiotic prescribing, 2010. NEngl J Med 2013, 368:1461-1462.
13. Viluksela M., Vainio P.J., Tuominen R.K. Cytotoxicity of macrolide antibiotics in a cultured human liver cell line. JAntimicrob Chemother 1996, 38:465-473.
14. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991, 91:40S-45S.
15. Lockwood A.M., Cole S., Rabinovich M. Azithromycin-induced liver injury. Am J Health Syst Pharm 2010, 67:810-814.
16. Longo G., Valenti C., Gandini G., et al. Azithromycin-induced intrahepatic cholestasis. Am J Med 1997, 102:217-218.
17. Chandrupatla S., Demetris A.J., Rabinovitz M. Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 2002, 47:2186-2188.
18. Juricic D., Hrstic I., Radic D., et al. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man. Basic Clin Pharmacol Toxicol 2010, 106:62-65.
19. Cascaval R.I., Lancaster D.J. Hypersensitivity syndrome associated with azithromycin. Am J Med 2001, 110:330-331.
20. AZITHROMYCIN. Available: . Accessed September 25, 2014. http://livertox.nih.gov/Azithromycin.htm.
21. Hoofnagle J.H. Drug-induced liver injury network (DILIN). Hepatology 2004, 40:773.
22. Fontana R.J., Watkins P.B., Bonkovsky H.L., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009, 32:55-68.
23. Vuppalanchi R., Hayashi P.H., Chalasani N., et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010, 32:1174-1183.
24. Rockey D.C., Seeff L.B., Rochon J., et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51:2117-2126.
25. Kleiner D.E., Chalasani N.P., Lee W.M., et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014, 59:661-670.
26. Suriawinata A., Min A.D. A33-year-old woman with jaundice after azithromycin use. Semin Liver Dis 2002, 22:207-210.
27. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy 2012, 97:1-17.
28. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011, 7:803-813. quiz 814-815.
29. Saha A., Das N.K., Hazra A., et al. Cutaneous adverse drug reaction profile in a tertiary care out patient setting in eastern India. Indian J Pharmacol 2012, 44:792-797.
30. Mittmann N., Knowles S.R., Koo M., et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol 2012, 13:49-54.
31. Williams D.A. Stevens-Johnson syndrome after erythromycin therapy while deployed at sea. Mil Med 2000, 165:636-637.
32. Reau N.S., Jensen D.M. Vanishing bile duct syndrome. Clin Liver Dis 2008, 12:203-217. x.
33. Mindikoglu A.L., Magder L.S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009, 15:719-729.